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ABSTRACT: Compstatin peptides are complement inhibitors
that bind and inhibit cleavage of complement C3. Peptide
binding is enhanced by hydrophobic interactions; however,
poor solubility promotes aggregation in aqueous environ-
ments. We have designed new compstatin peptides derived
from the W4A9 sequence (Ac-ICVWQDWGAHRCT-NH2,
cyclized between C2 and C12), based on structural, computa-
tional, and experimental studies. Furthermore, we developed
and utilized a computational framework for the design of
peptides containing non-natural amino acids. These new compstatin peptides contain polar N-terminal extensions and non-
natural amino acid substitutions at positions 4 and 9. Peptides with α-modified non-natural alanine analogs at position 9, as well
as peptides containing only N-terminal polar extensions, exhibited similar activity compared to W4A9, as quantified via ELISA,
hemolytic, and cell-based assays, and showed improved solubility, as measured by UV absorbance and reverse-phase HPLC
experiments. Because of their potency and solubility, these peptides are promising candidates for therapeutic development in
numerous complement-mediated diseases.
■ INTRODUCTION
The complement system is implicated in the onset and
progression of a number of autoinflammatory diseases.1 Despite
growing efforts to identify new complement-targeted ther-
apeutics, only one (eculizumab, Alexion) is currently in the
clinic.2,3 There is a growing need for new therapeutics to treat
chronic inflammatory diseases, which include age-related
macular degeneration (AMD), systemic lupus erythematosus,
and rheumatoid arthritis, among many others. Most comple-
ment therapeutics currently in clinical development are
biopharmaceuticals, which are prone to challenges in
production, delivery, and bioavailability. Few attempts at
developing low-molecular mass complement inhibitors have
been successful, largely because of the fact that complement
activation cascades are comprised of large protein−protein
interfaces and multimolecular complexes.3,4
Compstatin (Table 1, Parent) is a cyclic peptide that inhibits
complement activation (reviewed in refs 2, 4−14). It is one of a
small number of low molecular mass complement therapeutics
in development. The peptide binds to complement component
C3 (as well as its derivatives C3(H2O), C3b, and C3c), the
central protein of all complement activation cascades, and
prevents its cleavage to C3a and C3b, thus blocking generation
of complement effector proteins and complexes. Since its
discovery,5 the sequence of compstatin has been optimized to
improve its affinity and complement inhibitory activity.8,9,15−30
Numerous sequence modifications led to the development of
W4A9 (Table 1), the most active compstatin peptide with only
natural amino acids.20 Subsequently, many studies explored
incorporation of non-natural amino acids and modifications to
the compstatin sequence.20,22,23,26,29,30 Early studies of this type
led to development of meW4A9 (Table 1), which is currently
being pursued for treatment of AMD (clinicaltrials.gov,
identifier numbers NCT00473928 and NCT01157065).22
Determination of the structures of free (Parent)15 and C3c-
bound (W4A9)31 compstatin peptides paved the way for
further structure-based design and optimization of compstatin
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peptides. The solution NMR structure and subsequent
structure−activity studies by NMR identified two opposite
faces in compstatin, a hydrophobic face, proposed to be
important for binding and inhibitory activity, and a polar
face.8,9,15,17,19 The cocrystal structure revealed that compstatin
binding is dominated by hydrophobic interactions, accom-
panied by several hydrogen bonds.31 Recent efforts23−29 have
focused on modifying amino acids at positions previously
shown to tolerate mutations,8,9,15,17,18,32 but most designed
peptides exhibited no significant improvement in inhibitory
activity, and some had poor solubility. Consequently, molecular
dynamics (MD) simulations were used to explore the
possibility of incorporating additional polar amino acids at
the compstatin (W4A9) N-terminus and N-terminal exten-
sions.27 Incorporation of hydrophilic amino acids has been
recently reported to increase solubility of stapled peptides.33
Indeed, incorporation of Arg at position 1 and Ser-Ser and Arg-
Ser extensions at positions −1 and 0 showed similar inhibitory
activity and improved solubility compared to W4A9.28 This
improvement is attributed to increased polarity at the N-
terminus and the potential formation of additional polar
contacts (hydrogen bonds and salt bridges) with C3c.27,28
In this study, we sought to identify new compstatin peptides
with sequence modifications that promote both potent
complement inhibition and improved aqueous solubility.
Upon the basis of results from our previous study,28 we
designed peptides with varied polar N-terminal extensions. In
addition, we introduced a new computational approach for
peptide design with non-natural amino acids. We incorporated
non-natural amino acids (Figure 1) at positions 4 and 9, which
were previously shown to be amenable for inhibitory activity
optimization by the incorporation of non-natural amino
acids.20−22 These peptides, and combinations thereof, were
screened in functional in vitro and cell-based assays for
complement inhibitory activity and using absorbance spectros-
copy and HPLC for solubility and hydrophobicity. We
identified several new compstatin peptides with improved
pharmacological properties for potential therapeutic develop-
ment.
■ RESULTS
Building upon our recent studies,24,25,27,28 we designed new
compstatin peptides with the aim of simultaneously improving
inhibitory activity and aqueous solubility. Here, we incorpo-
rated components of de novo design, including a new method
for incorporation of non-natural amino acids, rational design
based on molecular dynamics simulations and previous
experimental data, and structure−activity relations. The
previously known top compstatin peptides, W4A9 and
meW4A9, include modifications at positions 4 and 9 (relative
to Parent), which enhance inhibitory activity by at least 10-fold
in various functional assays. While these modifications enhance
peptide inhibitory activity, they contribute to increased peptide
hydrophobicity, which has led to aggregation in aqueous
solution. Here, we introduced a new computational peptide
design method, which allows for the introduction of non-
natural amino acids, targeting positions 4 and 9 in order to
promote sequence diversity and explore new sets of possible
potent and soluble compstatin peptides. Peptides were
evaluated based on predicted physical interactions (contacts,
clashes, hydrogen bonds) with C3c and screened according to
Table 1. List of Compstatin Peptide Sequencesb
aPosition refers to residue number within each compstatin sequence.
For reference, the Cys residues are always at positions 2 and 12. bNon-
natural amino acid abbreviations: meW = L-1-methyltryptophan; Nal =
L-1-naphthylalanine; Rea = R-α-ethylalanine; Aal = R-α-allylalanine;
Sea = S-α-ethylalanine; 2Nl = L-2-naphthylalanine. All peptides (except
linear) are cyclized by a disulfide bond between C2 and C12.
Figure 1. Chemical structures of non-natural amino acids in
compstatin peptide sequences. The abbreviations used in sequences
(Table 1) are shown in parentheses.
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Figure 2. Concentration-dependent inhibition curves of compstatin peptides in C3b and C5b-9 ELISAs and hemolytic assays. Data show C3b, C5b-
9, and hemolysis inhibition (from left to right) for set 1 (A−C), set 2 (D−F), set 3 (G−I), set 4 (J−L), set 5 (M−O), and control (P−R) peptides.
Data points indicate mean percent inhibition ± SEM (standard error of the mean). The intersection of dashed lines shows the IC50 value for
meW4A9 in all plots. Curves to the right and left of the intersection point represent peptides with higher IC50 values and lower IC50 values compared
to meW4A9, respectively.
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computationally predicted binding affinity (K*), relative to
control peptides W4A9 and meW4A9 (Table S1 in Supporting
Information). We identified three peptides with higher
predicted binding affinity than both W4A9 and meW4A9
(peptides 1, 3, and 4), which were selected for experimental
evaluation. In addition, peptides with similar non-natural
modifications (peptides 2 and 5) were included in experimental
evaluation as well (Table 1, set 1).
Our most recent study showed that the N-terminal sequence
Arg-Ser-Ile forms additional polar and nonpolar contacts with
C3c, based on results from molecular dynamics simulations.27
Experimental data showed that peptide VI (from Gorham et al.,
2013, sequence Ac-RSICV{meW}QDWGAHRCT-NH2, cy-
clized by disulfide bridge) exhibited potent complement
inhibition (in in vitro and cell based assays) and improved
solubility (in UV absorption and RP-HPLC experiments).28
Therefore, we screened combinations of polar amino acids in
positions −1, 0, and 1 and evaluated predicted binding to C3c
relative to control peptides (Table S2). Six peptides were
identified with predicted C3c binding similar to or better than
W4A9/meW4A9 (Table S3), and three of these were selected
based on polarity (Table 1, set 2). In addition, the Arg-Ser-Ile
extension was tested without meW at position 4 (Table 1, set
2).
Additionally, we selected components of both sets of
peptides into two new sets, N-terminal extensions with Nal9
and N-terminal extensions with Nal4/9 (Table 1, sets 3 and 4).
Set 3 peptides were selected in order to balance the potential
interaction enhancement of Nal at position 9 with enhanced
solubility from polar N-terminal extensions. Set 4 additionally
included Nal at position 4, which was thought to improve
hydrophobic contacts with C3. In light of our results from the
first four sets of peptides and previous studies regarding
compstatin modifications,20 we combined selected features to
design peptides with optimal binding and solubility (Table 1,
set 5), and included Tyr at position 4 to improve solubility
(Tyr4 was previously shown to enhance inhibitory activity like
other aromatic amino acids at position 4).18,20,32
Complement Inhibition in ELISA and Hemolytic
Assays. We evaluated 20 newly designed compstatin peptides
(plus four controls) for complement inhibition in vitro. For
each peptide, we measured the ability to inhibit formation of
both C3b and C5b-9 in ELISA, as well as the ability to inhibit
complement-mediated lysis of rabbit erythrocytes in hemolytic
assays (Figure 2 and Table S4). We observe that for each
peptide, inhibition of the different complement effectors occurs
at similar concentration. This is in line with the ability of
compstatin peptides to block all complement pathways at the
C3 level and subsequent downstream activation. The newly
designed peptides exhibit similar or slightly reduced inhibition
(IC50 values equal or higher) compared to meW4A9/W4A9 but
were approximately an order of magnitude more potent than
Parent. Notably, peptides 3−5 from set 1 (Figure 2A−C) and
peptides 7−9 from set 2 (Figure 2D−F) show similar inhibitory
activity compared to meW4A9/W4A9. This effect is also
observed in the bar plots of Figure 3. α-Modified alanine
analogs at position 9 (in peptides 3−5) are conservative
substitutions, in terms of both C3 interaction and solubility,
and thus have similar inhibitory activity to meW4A9/W4A9.
Furthermore, polar N-terminal extensions seem to maintain
inhibitory activity (as shown previously),28 with the exception
of peptide 6, in which the negatively charged Glu residue may
destabilize intermolecular salt bridging interactions. All peptides
containing Nal at position 9 (peptides 1, 2, and 10−17)
required slightly higher concentrations for complement
inhibition, likely because of higher aggregation propensity.
However, some of the N-terminal extensions (i.e., Asn-Arg-Leu,
peptides 12 and 16) improved inhibition of the Nal9 peptides
(Figure 2G−L). The final set of peptides (set 5) showed
improved complement inhibition (Figure 2M−O) but
remained less potent compared to the aforementioned peptides
from sets 1 and 2. Indeed, previous work has shown that
incorporation of Tyr, Nal, or 2Nl at position 4 increased
inhibitory activity relative to Parent but had slightly less activity
compared to W4A9.20 We hypothesized that addition of the
polar RSI N-terminal extension may compensate for the
aforementioned activity loss while simultaneously improving
solubility. It seems that the extension neither improves nor
diminishes inhibition, and therefore, the slightly reduced
activity of set 5 peptides is most likely attributed to the
substitutions at position 4. W4A9 has an IC50 value
Figure 3. IC50 values for compstatin peptides. Bar plots show IC50
values for compstatin peptides 1−20 and positive control peptides
W4A9, meW4A9, and Parent in C3b ELISA (A), C5b-9 ELISA (B),
and hemolytic assay (C). Bars show mean IC50 from three
independent runs of each experiment (±95% confidence interval).
The dashed horizontal line shows the IC50 value for the meW4A9
control peptide, for ease of comparison.
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approximately 1 order of magnitude better than Parent in all
three assays (Figure 2P−R), which is in agreement with our
previous data.25,28 Interestingly, we observe that meW4A9 has
only slightly better inhibitory activity than W4A9 (within a 2-
fold difference), which differs from previous studies that report
nearly an order of magnitude difference in activity.22,23 We
expect this discrepancy is due to differences in biochemical and
functional assays used, as well as the aggregation propensity of
meW4A9.
Complement Inhibition in Retinal Pigmented Epithe-
lial Cell Model. A subset of peptides (peptides 5, 8, 12, 18,
and 19) was selected for evaluation of complement inhibition in
a retinal pigmented epithelial cell model, as described
previously.28 Selected peptides represent top-performing
peptides from each set (1−5), as determined through ELISAs
and hemolytic assays. All tested peptides significantly inhibited
complement activation (C5b-9/ApoE fluorescence) at 1 μM
concentration, compared to Linear and the positive control
(serum without inhibitor), and displayed similar complement
inhibition compared to W4A9 (Figure 4, Tables S5 and S6).
Notably, there was no significant difference in the levels of
complement activation between Parent and the positive control
or the linear peptide at 1 μM. This is likely due to the fact that
typical IC50 values for Parent range between 4 and 13 μM in
biochemical and functional assays (Figures 2 and 3, Table S4),
and 1 μM concentration is not sufficient to reduce complement
activation in RPE cells. To address this point, we tested higher
concentrations of Parent in the in vitro RPE cell assay. While
no complement inhibitory effects were noted for Parent at 1 or
10 μM, a significant (p-value of <0.001) inhibitory effect,
similar to that of the W4A9 peptide at 1 μM, was observed for
Parent at 50 μM (Figure 5). These results are consistent with
the results of C3b and C5b-9 ELISA analyses of complement
inhibition (Figure 2).
Solubility of Compstatin Peptides. Newly designed
compstatin peptides were tested for solubility via absorbance
measurements at 280 nm. The peptides showed a wide range of
solubility, ranging from 0.1 to >5 mg/mL (Table S7). Control
peptide meW4A9 showed moderate solubility in this assay (1.9
mg/mL), significantly lower than W4A9 and Parent, which
exhibited apparent solubilities of 3.2 and 4.5 mg/mL,
respectively. This result is consistent with the propensity of
meW4A9 to aggregate in aqueous environments.29,34,35
Peptides 1 and 2, which contain Nal at position 9, exhibited
the poorest solubility (∼0.1 mg/mL), much lower than all
control peptides. Addition of polar N-terminal extensions
(peptides 10−17) improved solubility only slightly (<0.4 mg/
mL). Peptides with α-modified alanine analogs at position 9
(peptides 3−5) showed much improved solubility, with values
near the detection limit in this assay (and similar to W4A9 and
Parent). These results show the importance of position 9 to
compstatin solubility. Indeed, solubility ranking follows the
trend Parent > W4A9 ∼ peptides 3−5 > peptides 1−2 ∼
peptides 10−17 and, in turn, His > Ala ∼ Rea ∼ Aal ∼ Sea >
Nal at position 9. Thus, increased hydrophobicity of residues at
position 9 strongly influences the solubility of compstatin
peptides. As in the case of complement inhibition, set 5
peptides showed intermediate solubility. There is likely a
balancing effect between the polar Arg-Ser-Ile N-terminal
extension and the hydrophobic residue (Tyr, Nal, or 2Nl) at
position 4. The importance of position 4 is also evidenced by
decreased solubility of peptides containing meW at position 4
(peptide 2 and meW4A9). Interestingly, while peptide 18 was
initially highly soluble (∼5 mg/mL), we observed a time-
dependent decrease in concentration when stored in a
polypropylene tube (Figure 6, Table S7). Thus, it is unclear
whether the change in solubility of peptide 18 is due to time-
dependent aggregation or simply interaction with the container.
It should be noted that while complement inhibitory activity of
compstatin peptides has been associated with increased
hydrophobicity in past studies,25,28,29 we observed that
solubility is in fact associated with inhibitory activity (Figure
6). This is a direct result of our peptide design, as we
engineered polar residues in regions of compstatin that should
Figure 4. Effects of compstatin peptides on complement activation in
the RPE cell in vitro assay. The ratio of C5b-9/ApoE fluorescence
(±SEM, n = 10) is plotted as a percentage of the positive control
(POS) for two hfRPE cell lines, 072810 (gray) and 081309 (black).
Untreated cells that were not incubated with complement-competent
human serum served as negative control (NEG). At 1 μM, the parent
compound is not significantly different from the positive or linear
peptide controls. All test peptides (W4A9, PEP 5, PEP 8, PEP 12, PEP
18, and PEP 19) displayed significant complement inhibition relative
to their corresponding positive control (see Tables S5 and S6).
Figure 5. Effects of varying concentrations of Parent on complement
activation in the RPE cell in vitro assay. The ratio of C5b-9/ApoE
fluorescence (±SEM, n = 10) is plotted as a percentage of the positive
control. Parent was tested at concentrations of 1, 10, and 50 μM
(PAR1, PAR10, and PAR50). The concentration of W4A9 was 1 μM.
All values are expressed relative to the positive control. Parent shows
no significant difference from the positive control at 1 μM or 10 μM
concentrations. At 50 μM the effect of Parent is equivalent to that of 1
μM W4A9. Both Parent at 50 μM and W4A9 at 1 μM are significantly
different than the positive control (p-value of <0.001, two-tailed
Mann−Whitney U test).
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not affect binding. A clear exception to the aforementioned
trend is Parent, in which solubility-enhancing substitutions are
at positions that strongly influence binding.
Relative Lipophilicity of Compstatin Peptides. Mod-
ifications of peptide amino acid content can have a significant
effect on peptide inhibitory activity, solubility, and lip-
ophilicity.36 The inhibitory activity of the compstatin peptides
depends in part on hydrophobic interactions with C3, which
can be mimicked by the interactions of hydrophobic amino acid
side chains of the peptides with the C18 HPLC stationary
phase. The retention time of each peptide on the HPLC
column can be used to calculate logarithm of the retention
factor (log(k)), which is related to its lipophilicity (and
hydrophobicity). Figure 7 shows log(k) values for compstatin
peptides. A full summary of RP-HPLC retention times,
retention factors (k), and log(k) values are summarized in
Table S8, with the peptides organized according to substitution
patterns. The peptides are listed in order of increasing relative
lipophilicity in Table S9. As expected, peptide lipophilicity is
inversely related to solubility with an R2 = 0.72 (Figure S1).
Modifications of peptide sequence can have a large effect on
their RP-HPLC retention behavior. Comparison of the HPLC
results for peptides 2 and 10−13 demonstrates that addition of
the charged and polar amino acids at positions −1, 0, and 1
reduces the retention time while substitution of the hydro-
phobic L-1-naphthylalanine (Nal) for Trp increases the
interaction with the stationary phase. Peptides 14−17 are
more retained than peptides 10−13, which differ in structure
only by a Nal substitution at position 4. Peptides 1 and 2 also
contain Nal at position 9 in place of Ala in structurally similar
peptides meW4A9 and W4A9, respectively, and are more
highly retained than these analogs. A similar observation can be
made when comparing peptides 9 and 19, which differ at
position 4 by the substitution of Nal. Substitution of Tyr for
Trp in peptide 18 reduces its interaction with the stationary
phase as reflected by its smaller value of log(k).
Structural modifications of amino acid residues can also affect
the interactions of peptides with the hydrophobic stationary
phase. For example, the addition of a methyl group to a Trp
residue at position 4 increases the retention compared with the
Trp analogs. Peptides 1 and meW4A9 are more highly retained
than peptides 2 and W4A9, respectively. The position of the
naphthyl addition on alanine also affects the interaction of the
peptide with the stationary phase. Peptide 19, which contains L-
1-naphthylalanine, is less retained than peptide 20, which
contains L-2-naphthylalanine at the same position. Similarly,
peptides 3 and 5, which differ only by substitution of R- and S-
α-ethylalanine, respectively, can be resolved by HPLC with
peptide 3 being more highly retained than peptide 5.
■ DISCUSSION
Although continual efforts to improve compstatin have yielded
peptides with potent complement inhibition, many are
characterized by poor solubility in aqueous environments
containing physiological ionic strength.22,25,28,29 The inhibitor
meW4A9 (AL-78898A, Alcon)29 has recently completed phase
II clinical trials (clinicaltrials.gov, identifier numbers
NCT00473928 and NCT01157065) for AMD; however, the
results showed that this peptide did not yield reduced retinal
thickness in AMD patients in comparison to ranibizumab
(Genentech/Novartis),14 a current AMD therapeutic. It is likely
Figure 6. Relation between activity and solubility of compstatin
peptides. IC50 values for compstatin peptides in C3b ELISA (A), C5b-
9 ELISA (B), and hemolytic assay (C) are plotted against solubility.
Horizontal and vertical error bars represent the standard deviation and
95% confidence intervals of solubility and IC50, respectively. Points
inside the ellipse (lower right corner) have a favorable balance
between activity and solubility. Note the peptide 8 solubility was
measured using less starting material compared to the rest, and thus,
its solubility is not directly comparable to that of other peptides.
Figure 7. RP-HPLC retention factors for compstatin peptides. Bar
plots show log(k) values for compstatin peptides 1−20 and positive
control peptides W4A9, meW4A9, and Parent in C3b ELISA. The
dashed horizontal line shows the log(k) value for the meW4A9 control
peptide, for ease of comparison.
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that the low aqueous solubility of meW4A9 contributes to its
poor performance.29,34,35 Thus, recent studies have aimed at
improving solubility of compstatin peptides while simulta-
neously maintaining or improving complement inhibitory
activity.
In this study, we designed and tested new compstatin
peptides with diverse polar N-terminal substitutions and
extensions. We also employed a new computational design
framework for non-natural amino acids to identify non-natural
amino acids at positions 4 and 9 predicted to improve C3
binding. Furthermore, we tested peptides containing combina-
tions of these features, selected using rational design arguments.
We note that all of our designed peptides have inhibitory
activities similar to controls meW4A9 and W4A9 and
significantly better than Parent (Figures 2−5). Most
importantly, we found that peptides containing either α-
modified non-natural alanine analogs at position 9 (peptides 3,
4, and 5) or N-terminal natural amino acid extensions (peptides
7, 8, and 9) have inhibitory activity similar to meW4A9 while
exhibiting greatly improved aqueous solubility. Given the
clinical interest in meW4A9 for treatment of a variety of
complement-mediated disorders, in conjunction with problems
recently encountered in clinical trials, we believe that our newly
designed compstatin peptides (i.e., peptides 3, 4, 5, 7, 8, and 9)
represent more promising therapeutic alternatives.
Several recent studies have focused on improving affinity of
compstatin peptides.23,25,26,28,29 Indeed, some compstatin
peptides bind to C3 with affinities of <1 nM, with
correspondingly low IC50 values in complement assays.
29
While improved affinities are attractive for therapeutic design
when taken at face value, we must remain aware that human
plasma C3 concentrations are at least 5 μM, and thus high
compstatin concentrations are required for therapeutic efficacy
despite high binding affinity. Consequently, we conclude that
(a) it is unnecessary to further improve compstatin binding
affinity and inhibitory activity and (b) compstatin must be
highly soluble to inhibit C3 cleavage in vivo. It is now crucial to
focus on improving pharmacological properties of compstatin
peptides. Recent studies have addressed several of these
properties, including solubility, half-life, and degrada-
tion.28−30,37 We have identified several highly soluble
compstatin peptides with potent inhibitory activity. In the
past, it was thought that a high degree of hydrophobicity was
required for potent compstatin activity. We illustrate here that
the incorporation of N-terminal extensions can help to
circumvent this activity−hydrophobicity/solubility paradigm.
Our inhibitory activity versus solubility data (Figure 6) denote
peptides with similar inhibitory activity compared to highly
active controls (i.e., meW4A9) but with improved solubility
characteristics. Furthermore, several peptides (peptides 6−9
and 18) are notably less lipophilic than both meW4A9 and
W4A9 (Figure 7 and Table S9). These peptides, as well as
additional peptides containing alternative combinations of top-
performing modifications, represent promising candidates for
therapeutic development, for treatment of a wide variety of
complement-mediated autoinflammatory diseases.
■ EXPERIMENTAL SECTION
De Novo Peptide Design with Natural Amino Acids.
Sequence selection, fold specificity, and approximate binding affinity
calculations for natural amino acid design were performed following
the procedure described previously in Protein WISDOM and are
described below.38 The purpose of the design was to produce novel
natural amino acid sequence extensions using the previously designed
sequences Ac-RSICVWQDWGAHRCT-NH2 (sequence of peptide 9
in Table 1, called RSI hereafter) and Ac-SSICVWQDWGAHRCT-
NH2
27,28 (called SSI hereafter) as templates. Both sequences are
identical to the W4A9 variant of compstatin with two positions added
to the N-terminus, termed positions −1 and 0. These sequences were
used as input to further design these positions for C3c binding. RSI
was chosen as a design template, as it previously yielded improved IC50
values relative to W4A9 in C3b ELISA and hemolytic assays, as well as
significant complement inhibition according to a human retinal
pigmented epithelial cell-based model mimicking drusen biogenesis.28
SSI had near W4A9 calculated affinity for human C3 and
simultaneously high calculated affinity for non-primate C3.27 Because
of the previous designs of both of these sequences, MD simulations
were previously performed and therefore were utilized as design
templates in this next generation of design.
Sequence Selection. The peptide structure template for sequence
selection was constructed based on the structure of the W4A9 analog
(PDB code 2QKI).31 Molecular dynamics simulations of the template
compstatin extensions were performed previously and were used as a
flexible template for this design.28 In all cases, both extended positions,
−1 and 0, as well as the adjacent position 1, were allowed to mutate.
Because of the relatively small sequence space in this study (three
mutatable positions only), the three positions were allowed to mutate
to all possible amino acids except for proline and cysteine, which were
excluded because of their unique chemical and geometric properties.
The centroid−centroid potential energy function was used as the input
force field,39 which serves as a look-up table of energies of all
combinations of amino acid pairs at a fixed set of distance bins.
The flexible distance−bin sequence selection method38 was used to
solve for a rank-ordered list of low energy sequences according to the
following model.
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The set i = 1, ..., n defines each residue position in the design template.
At each position i, mutations are represented by j{i} = 1, ..., mi, where
mi = 20 if the sequence position is allowed to mutate to any of the 20
natural amino acids. Alias sets k ≡ i and l ≡ j, with k >i, are used to
represent the pairwise interactions between all residue positions and
amino acid types. The decision variables yi
j and yk
l are solved for in
order to determine the amino acid types in each position. The yi
j
variable will assume the value of 1 if the model assigns amino acid j to
position i and assume the value of zero otherwise (similarly for yk
l ).
The objective function represents the sum of all pairwise energy
interactions in the design template.38 The model incorporates the
distance information from the template structures by introducing a
binary variable bikd, which equals 1 if the distance between residues i
and k falls within distance bin d and equals zero otherwise. The
parameter disbin(xi, xk, d) equals 1 if the distance between residue
positions i and k in any of the input template structures falls into
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distance bin d and equals zero otherwise, which forces only one
distance bin per amino acid pair to contribute to the total energy.38
Since we started with template structures with sequences of both
RSI and SSI, three separate runs were performed for the design. Run 1
used only the RSI structures as the input template. Run 2 used only
SSI structures as the input template, and run 3 used a combined RSI
and SSI structure set as the input template. For each run, 500 low-
energy sequences were generated using the flexible distance−bin
sequence selection method. From runs 1−3, a consensus set of
sequences was constructed from the 1500 total sequences generated.
This resulted in a total of 1019 sequences, which were then validated
using the fold specificity metric.38
Fold Specificity. The aim of the fold specificity calculation is to
determine the stability of a designed sequence in the target template
structure as compared to the stability of the native sequence. The
flexible template structure defined bounds on the minimum and
maximum Cα−Cα distances and φ and ψ angles experienced.
Ensembles are next generated using a torsion angle dynamics
simulated annealing containing 500 conformers using CYANA
2.1.40,41 A local energy minimization is performed on every conformer
in TINKER 3.642 using the AMBER force field,43 and the final
potential energy of each conformer is tabulated. The energetics of the
native sequence is similarly tabulated. The fold specificity calculation is
next performed as
=
∑
∑
β
β
∈
−
∈
−f
e
e
i
E
i
Espec
novel
native
i
i (2)
with more positive values being favorable.38
Three separate runs of fold specificity were performed, based on
which template structures were used in the calculation: run 1 using
RSI structures only, run 2 using the SSI structures only, and run 3
using the combined RSI and SSI structure set. The sequences were
then rank-ordered by fold specificity for each set, and a consensus set
of sequences was determined for validation using approximate binding
affinity (Table S2). Sequences were chosen for validation to maximize
fold specificity across runs, as well as to cover a large chemical space.
This resulted in 15 sequences with mutations in positions −1, 0, and 1
and in 7 sequences with mutations in positions −1 and 0 only.
Approximate Binding Affinity. The approximate binding affinity
calculation in Protein WISDOM consists of several steps, which
include diverse ligand ensemble generation, clustering, docking, and
final ensemble generation. The goal is to generate a diverse ensemble
of docked ligand poses to the receptor to assess the relative energetics
of the complex, receptor, and ligand through calculation of
approximations of their partition functions. The approximate binding
affinity44 is defined as K* = qPL/(qPqL), where qPL =∑b∈B e−[Eb/(RT)], qP
=∑f∈F e−[Ef/(RT)], and qL =∑l∈Le−[Ei/(RT)] are the partition functions of
the protein−ligand complex, the free protein, and ligand, respectively.
The sets B, F, and L, contain rotamerically based conformations of the
bound complex, free protein, and free ligand. En is the energy of each
conformation. R is the gas constant, and T is the temperature.
Two-thousand structures for each candidate compstatin extension
sequence are generated using the Rosetta AbRelax function as part of
the Rosetta 3.4 package.45−47 Monte Carlo sampling is used to replace
local protein structures with structural fragments derived from
homologous sequences. The structures are clustered based on their
φ and ψ angles using OREO.48,49 The average structure from the 10
largest clusters and the lowest energy structure are chosen for docking
to the target protein. This yields 11 structures with unique backbones
which are next docked using RosettaDock.50 The 10 lowest energy
docked poses for each of the 11 ligands are passed to RosettaDesign51
to generate 200 rotamer conformations per starting complex structure
(22 000 total states representing the bound set). The ligand ensemble
is constructed by taking the 10 lowest energy structures from each of
the 10 largest clusters plus the 10 lowest overall energy peptide
conformations and generating 200 rotamer conformations (22 000 free
ligand structures) for each. The protein ensemble is generated directly
by assembling 2000 rotamer structures from the single starting C3c
structure. With these ensembles and their corresponding Rosetta
energies, the K* is calculated.
The 22 sequences from fold specificity were run through the
approximate binding affinity protocol38 in order to determine which
designed peptides were predicted to bind more strongly than the
W4A9 peptide. Of the 22 tested peptides, six peptides were predicted
to have higher binding affinity than W4A9 and peptide 9. The
sequences of these peptides are provided in Table S3. Of these six
peptides, three were selected for further experimental testing.
De Novo Peptide Design with Non-Natural Amino Acids.
Recently, efforts have expanded to create methods for designing non-
natural amino acids into proteins.52−60 We have created new force
fields based on quantum chemical calculations for post-translational
modifications and unnatural amino acids for AMBER.61,62 Thus, we
developed a novel framework combining our force fields, integer linear
optimization, and molecular dynamics simulations to aid us in
generating lead compounds for experimental exploration. The first
step in the procedure is to derive candidate sequences containing post-
translational modifications and non-natural amino acids. The overall
idea is that we want to introduce modified amino acids to enhance the
number of contacts and hydrogen bonds relative to the starting
peptide while minimizing the clashes introduced by the modified
amino acid. In addition, we want to preserve the local electrostatic
landscape and any salt-bridges that are formed between the original or
designed sequence scaffold and the target receptor. This is modeled as
the following integer linear optimization problem:
∑ ∑ ∑
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with the following sets, parameters, and binary decision variables.
Sets:
p ∈ (1, 2, ..., Npositions); this is the set of positions in the amino
acid sequence.
Np ⊆ (Ala, Arg, Asn, ..., Tyr); this is the native amino acid in each
position p.
M ∈ (Np, ..., PTMs, ..., Non-naturalAminoAcids); this is the
universe of modification types under consideration for which we have
derived parameters for. This universe comes from a limited set of
modifications parametrized early on for Forcefield_PTM61 and
Forcefield_NCAA.62
C ∈ (1, 2, 3, ..., Ncomplexes); this is the set of complex configurations.
Ω is the set of complex positions that correspond to the lowest
energy configurations from a molecular dynamics simulation, an NMR
structural ensemble, or a single crystal structure. Note that the set M
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contains all the post-translational modifications and unnatural amino
acids for which we have parameters for, as well as the native amino
acid in position p being designed. Modified amino acid parameters
were taken from Forcefield_PTM61 and Forcefield_NCAA.62
Parameters:
Cm
p , charge of modification m at position p.
Dp, charge of original amino acid on template sequence at position
p.
Hm
p , hydrophobicity of modification m at position p.
Hp, hydrophobicity of original amino acid on template sequence at
position p.
goodcontacts(C,m,p), number of contacts between modification m
at position p and the receptor with van der Waals radii overlap of
atoms (i,j) ≥ −2 in configuration C.
clashes(C,m,p), number of contacts between modification m at
position p and adjacent residues in the peptide or the receptor with a
van der Waals radii overlap of atoms (i,j) ≥ 0 or ≥ 0.4 if atoms (i,j)
can potentially hydrogen bond in configuration C.63
hbonds(C,m,p), number of valid hydrogen bonds (distance and
angle orientation) between modification m at position p and the
receptor in configuration C.63,64
IE(C,m,p), energy of binding between protein and peptide in
configuration C as a result of modifying position p to modification type
m, where this energy is defined as
− −E E Ecomplex protein ligand
sp(p) = 1 if position p is allowed to be modified, 0 otherwise.
S(C,m,p) = 0.1 goodcontacts(C,m,p) − 5 clashes(C,m,p) +
1 hbonds(C,m,p), weighted contact score of modification m at
position p in configuration C. This score is not an energy that is
physically derived but a tabulation of quantities of interactions.
Natural amino acids are classified as hydrophobic or hydrophilic if
their relative side chain solvent-accessible surface areas (SASAs)
calculated with the program NACCESS65 in their position in three-
dimensional space within the context of the complex are ≤20 or ≥50,
in accordance with work by Bellows et al.24 Introducing hydro-
phobicity constraints in previous designs using only natural amino
acids was observed to be a critical component to successful
design.24,66−69 Next, we define Mp ⊆ M, which is the subset of
modifications meeting the charge and hydrophobicity constraints
below at position p, ∀ positions p. This set, derived from the following
constraints, reduces the search space.
Constraints That Must be Met for Inclusion in Set Mp. Local
charge/salt-bridges must be conserved in each position p
∑ = ∀
∈
C D p
m M
m
p p
(4)
Local hydrophobicity must be conserved at each p
∑ = ∀
∈
H H p
m M
m
p p
(5)
We further want to limit the modifications to those that are of the
same type as the native amino acid in position p. For example, if the
native amino acid in position 5 were a tyrosine, we would allow only
for modifications of tyrosine as design choices and not modifications
of alanine. Therefore, we define Mp
Np ⊆ Mp as the subset of
modifications in position p that are allowed given the native amino
acid in position p, Np. Utilizing this subset dramatically reduces the
search space.
There are geometric conditions required for a contact, clash, and
hydrogen bond to occur. These conditions reflect the fact that two
atoms that hydrogen bond may come closer to each other than their
van der Waals radii would normally allow. Contacts, clashes, and
hydrogen bonds were evaluated between the modified position of the
compstatin analog and C3c using custom scripts interfacing with
UCSF Chimera.64 Intermolecular contacts were defined with an
overlap cutoff of −2 and a hydrogen bond allowance of 0. Both inter-
and intramolecular clashes were calculated with an overlap cutoff of 0.4
and a hydrogen bond allowance of 0.4. Intermolecular hydrogen bonds
were calculated between compstatin analogs and C3c with a 0.4 Å
distance relaxation and a 20° angle relaxation from the default
hydrogen bond criteria.
Binary Decision Variables. ym
p = 1 if modification m is assigned to
position p, 0 otherwise.
The objective function, eq 3a, aims to maximize a Boltzmann-
weighted contact score. Equation 3b defines the weights of the contact
score as a weighted sum of goodcontacts, clashes, and hbonds. The
goal of the contact score is to improve affinity/specificity through the
optimization of shape-complementarity at the individual amino acid
level. It rewards good contacts and hydrogen bonds while strongly
penalizing unfavorable clashes. Equation 3c defines a position-specific
partition function. This quantity becomes the denominator for the
Boltzmann-weighted contact score so that for each position, a
probability can be derived based on the sum over the allowed
modification types m ∈ Mp
Np and complex configurations C. Equation
3d defines the Boltzmann factor that is the ratio of the exponent of the
weighted contact score, eq 3b divided by the position-specific partition
function, eq 3c. The constraint 3e states that the average energy of
binding across all complex configurations must remain favorable for
the modification m to be chosen in position p. This is important to
preserve the local electrostatic interactions of the template sequence if
any are present. Equation 3f states that only one amino acid is allowed
to be selected in each position. Equation 3g is the integer cut
constraints that generate a rank-ordered list of optimal solutions.
Equation 3h indicates that the decision variables ym
p are binary.
A computational pipeline to design proteins and peptides by
introducing non-natural amino acids was created. The pipeline takes as
input design positions, as well as a set of complex configurations
corresponding to a peptide with natural amino acids bound to a
receptor protein. These configurations were the single state of the
C3c:W4A9 crystal structure (PDB code 2QKI).31 Trp4 and Ala9 were
selected as design positions. Next, the initial energy of binding, charge,
and hydrophobicity constraints are populated using AMBER 1170 and
Chimera.64 Then for each complex configuration and each allowed
modification in each design position, the complex is modified at the
specified design position, a local energy minimization is performed,
and the contacts, clashes, hydrogen bonds, and binding energies are
populated. The AMBER program tleap was used to construct the
modified side chains according to their orientations defined in
Forcefield_PTM61 and Forcefield_NCAA.62 In position 4, tryptophan,
5-hydroxytryptophan, 5-methyltryptophan, N-methyltryptophan, 1-
methyltryptophan, and 7-hydroxytrptophan were evaluated. In
position 9, alanine, 1-naphthylalanine, N-methylalanine, pyrenylala-
nine, (R)-α-ethylalanine, (S)-α-ethylalanine, and R(+)-α-allylalanine
were evaluated. These were chosen as they met the criteria to be
included in each of their respective sets MP
NP, and their parameters were
included in Forcefield_PTM or Forcefield_NCAA. For each
modification upon construction, 1500 steps of steepest descent
followed by 500 steps of conjugate gradient minimization were
performed to relax the new non-natural side chain placement in the
context of compstatin and the C3c receptor. The implicit solvent
model by Onufriev71,72 (igb = 5) was utilized in all AMBER
calculations. After population of this information for all complex
configurations, the integer linear optimization model presented above
is solved to global optimality, generating a rank-ordered list of
modified amino acid substitutions.
The sequence solutions were next simulated in AMBER 11 to assess
the approximate binding affinity (K*) with a procedure described
previously.62 Specifically, three independent simulations are carried
out of the complex, protein, and peptide. A single simulation of the
protein was used to assess its energetic contributions. Structures were
minimized with 600 steps of steepest descent with 400 steps of
conjugate gradient minimization to relax the new side chains. The
structures were heated in six stages over 30 ps from 0 to 300 K. Shake
constraints were used for all simulation steps on the heavy-atom to
hydrogen bonds, and a nonbonded interaction cutoff of 16 Å was used.
Each C3c:compstatin peptide candidate sequence underwent short 0.5
ns production simulations using a 1 fs time step at 300 K. The
theoretical foundation for this calculation was previously described in
Journal of Medicinal Chemistry Article
DOI: 10.1021/jm501345y
J. Med. Chem. 2015, 58, 814−826
822
Khoury et al.62 and Lilien et al.44 Those sequences with the highest K*
values relative to the control peptide W4A9 were proposed for
experimental testing (Table S1). We note that the approximate
binding affinity is used as a metric to select which peptides may be
promising62 candidates for testing based on physics-based potentials,
and we do not attempt to compare the calculated values to the exact
experimental values. Instead, we aim to utilize metrics that increase our
probability that top ranked peptides are indeed inhibitors of C3.
Peptide Synthesis. Compstatin peptides 1−9, 14−20, W4A9,
meW4A9, and Parent were synthesized by WuXi AppTec (Shanghai,
China). Peptides 10−13 were synthesized by Genscript, Inc.
(Piscataway, NJ, USA). Linear (negative control) was obtained from
either Tocris Bioscience (Bristol, U.K.) or WuXi AppTec. All peptides
were of >95% purity, as determined by HPLC and MS. Non-natural
amino acids used in this study included L-1-methyltryptophan, L-1-
naphthylalanine, L-2-naphthylalanine, R-α-ethylalanine, R-α-allylala-
nine, and S-α-ethylalanine (Figure 1). Peptides containing L-1-
methyltryptophan were synthesized using Fmoc-1-methyl-DL-trypto-
phan (commercially available preparation) and subsequently purified
by HPLC.
Solubility Measurements. Approximately 1 mg of each tested
peptide was dissolved in 200 μL of PBS, pH 7.4. It should be noted
that the resulting concentration yields saturated solutions for only
some peptides, and the maximum solubility reported here is thus 5
mg/mL. Samples were vortexed for 30 s each, then centrifuged at
13000g for 5 min. Supernatant was collected and measured
spectrophotometrically at 280 nm, using a NanoDrop Lite
spectrophotometer. Absorbance measurements were converted to
concentration using the Beer−Lambert law. Molar extinction
coefficients were calculated for each peptide based on the number of
Trp and Tyr residues in their sequences. Because of their aromatic
properties, L-1-methyltryptophan, L-1-naphthylalanine, and L-2-naph-
thylalanine also contribute to absorbance at 280 nm. Molar extinction
coefficients used for these amino acids were 5470 M−1 cm−1,28 3936
M−1 cm−1,20 and 3936 M−1 cm−1, respectively (the coefficient for L-2-
naphthylalanine was assumed to be equal to that of L-1-
naphthylalanine). Dissolved samples were stored at 4 °C, and
measurements of the same samples were repeated at 24 and 48 h
time points. Measurements represent the mean and standard deviation
of three measurements performed on the each sample.
C3b and C5b-9 ELISA. Nunc Maxisorp 96-well microtiter plates
were coated with 20 μg/mL lipopolysaccharides (LPS) from
Salmonella enterica serotype enteritidis (Sigma-Aldrich, St. Louis,
MO, USA) for 16 h at ambient temperature. Plates were washed three
times with PBS (containing 0.05% Tween-20; PBS-T) between each
incubation step. Plates were blocked with 4% BSA in PBS-T for 1 h at
37 °C. Lyophilized compstatin peptides were initially dissolved in PBS,
pH 7.4, and concentration was measured spectrophotometrically at
280 nm. Serial dilutions of each peptide were prepared in veronal-
buffered saline containing 0.1% gelatin, 5 mM MgCl2, and 10 mM
EGTA (GVBS-MgEGTA). Normal human serum (Complement
Technology, Inc., Tyler, TX, USA) was dissolved in GVBS-MgEGTA
and was preincubated with peptide dilutions (or buffer) for 15 min at
ambient temperature. Samples were subsequently incubated in blocked
plates for 1 h at 37 °C. After incubation, plates were incubated with
either horseradish peroxidase (HRP) conjugated anti-C3 (MP
Biomedicals, Solon, OH, USA) or anti-C5b-9 aE11 (Abcam,
Cambridge, MA, USA) for 1 h at 37 °C. C5b-9 detection additionally
involved incubation with an HRP-conjugated secondary antibody, also
for 1 h at 37 °C. Levels of C3b and C5b-9 deposition were measured
using a 3,3′,5,5′-tetramethylbenzidine substrate solution containing
urea hydrogen peroxide in 0.11 M sodium acetate buffer, followed by
addition of 1 N H2SO4. Plates were subsequently measured
spectrophotometrically at 450 nm.
Hemolytic Assays. Rabbit erythrocytes (Complement Technol-
ogy, Inc., Tyler, TX, USA) were washed and resuspended in veronal-
buffered saline containing 5 mM MgCl2 and 10 mM EGTA (VBS-
MgEGTA). Normal human serum and compstatin peptides (serial
dilutions) were diluted in VBS-MgEGTA and preincubated together in
round-bottom 96-well plates for 15 min at ambient temperature. 5 ×
106 rabbit erythrocytes were added to each well, and plates were
incubated for 20 min at 37 °C. Erythrocytes in either deionized water
or normal human serum (dissolved in VBS-MgEGTA) were used as
positive controls for lysis, and erythrocytes in either VBS-MgEGTA or
normal human serum (dissolved in VBS-EDTA) were used as negative
controls for lysis. Reactions were quenched by adding ice cold VBS
(containing 50 mM EDTA) to each well. Plates were centrifuged at
1000g for 5 min, and supernatant was diluted 1:1 in deionized water in
new plates. Lysis was quantified spectrophotometrically at 405 nm.
RPE Cell Culture. The RPE cell-based in vitro model of drusen
formation73 was employed as previously described.28 Human fetal RPE
cells (Advanced Bioscience Resources, Alameda, CA) were cultured on
Millipore HA porous supports (Millipore, catalog no. PIHA 01250) in
Miller medium supplemented with 5% fetal calf serum (FCS). RPE cell
cultures derived from two different donor eyes (line no. 081309 and
line no. 072810) were used. Samples were rinsed in PBS and then
individually exposed to an experimental peptide in serum-free Miller
medium containing 10% human complement serum (Innovative
Research, catalog no. IPLA-CSER AB, lot no. L12402). The 1 μM
peptide concentration employed was previously shown to be in the
linear range of inhibitory concentrations during titrations.28 One
experiment employed the parent compound at 1, 10, and 50 μM.
Negative control cells were exposed to Miller medium + 5% FCS;
positive control cells were exposed to Miller medium + 10% human
complement serum. Experimental and control solutions (1 mL) were
mixed on a rocker at room temperature for 30 min, then warmed to 37
°C, before sample exposure and overnight incubation at 37 °C in a
7.0% CO2 incubator. Following this period, the samples were rinsed
with warm, sterile PBS, fixed in cold 4% paraformaldehyde (PFA) in
PBS for 20 min, and stored in 0.4% PFA until use in
immunohistochemical assays.
Immunohistochemistry. After rinsing the fixed samples in PBS,
the inset membrane was excised with a scalpel and cut into ∼4 mm2
squares. Duplicate samples from each condition were embedded in
10% agarose (Type XI, Sigma-Aldrich, catalog no. A3038) and
sectioned at 100 μm using a vibratome. Sections were blocked with
normal donkey serum (1/20 in PBT/PBS containing 0.5% bovine
serum albumin and 0.1% Triton X-100) overnight at 4 °C. The
sections were co-incubated with two primary antibodies (polyclonal
goat anti-ApoE, Millipore catalog no. AB947, 1/1000 in PBT, and
mouse monoclonal anti-C5b-9, Dako catalog no. MO777, 1/200 in
PBT) overnight at 4 °C, then rinsed in PBT, and then co-incubated in
secondary antibodies (Alexa Fluor 546-conjugated donkey anti-goat
IgG and Alexa Fluor 488-conjugated donkey anti-mouse IgG, both 1/
200 in PBT, Life Technologies catalog no. A-11056 and no. A-21202)
overnight at 4 °C. The immunolabeled sections were then rinsed in
PBT, stained with Hoechst 33342 (Life Technologies catalog no.
H3570), and mounted on slides with Prolong Gold (Life Technologies
catalog no. P36930).
Confocal Imaging and Analysis. Samples were imaged with an
Olympus FV1000 confocal laser scanning microscope. Ten single-
plane images, captured at a resolution of 1024 × 768 pixels and saved
as 24-bit tiff files, were acquired for each sample. Digital image files
were analyzed using MetaMorph software (Molecular Devices,
Sunnyvale, CA). For image quantification, the area of C5b-9 specific
fluorescence was normalized to the area of ApoE specific fluorescence
and expressed as the C5b-9/ApoE ratio. Statistical significance was
determined using the Mann−Whitney U test with p-value of ≤0.05
considered significant.
RP-HPLC Study. The relative lipophilicity of compstatin peptides
was determined using RP-HPLC.28,74 This method has been used to
evaluate the retention factor, k, of peptides between the hydrophobic
stationary phase and hydrophilic mobile phase. The logarithm of the
retention factor was determined based on the peptide retention time,
tR, and column dead time, t0.
28 These peptides are structurally similar,
some differing by only one site or position of substitution. The
isocratic RP-HPLC method used in this work allows for comparison of
the interaction of the structurally similar peptides with the hydro-
phobic stationary phase.
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The separations were performed using an Agilent 1100 HPLC with
UV detection at 280 nm and a Waters (Milford, MA, USA) 4.6 mm ×
150 mm XTerra MS C18 column with 5 μm particles and a 125 Å pore
size. The peptides were eluted using a mobile phase A, consisting of 10
mM phosphate buffer at pH of 7.4 with 1% TFA, and acetonitrile as
mobile phase B. The peptides were first evaluated using method 1,
running 32% B isocratically at a flow rate of 1.0 mL/min at 25 °C. The
less hydrophobic peptides 3−9 and 18−20 were better resolved using
isocratic method 2 which used 28% B. Triplicate 10 μL injections were
performed for each peptide at concentrations ranging from 9 to 16
μM. The column dead time was determined to be 1.418 ± 0.004
(method 1) and 1.425 ± 0.006 (method 2) using a 5 mg/mL solution
of aspartic acid as the unretained analyte.28
Dibasic sodium phosphate, aspartic acid, and acetonitrile were
purchased from Fisher Scientific (Pittsburgh, PA, USA). Trifluoro-
acetic acid (TFA) was purchased from Acros (Geel, Belgium). HPLC-
grade water was obtained from Burdick and Jackson (Muskegon, MI,
USA).
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A.; Kraszni, M.; Kieslich, C. A.; Banna, C. D.; Bellows-Peterson, M. L.;
Larive, C. K.; Floudas, C. A.; Archontis, G.; Johnson, L. V.; Morikis, D.
Novel compstatin family peptides inhibit complement activation by
drusen-like deposits in human retinal pigmented epithelial cell
cultures. Exp. Eye Res. 2013, 116C, 96−108.
(29) Qu, H.; Ricklin, D.; Bai, H.; Chen, H.; Reis, E. S.; Maciejewski,
M.; Tzekou, A.; DeAngelis, R. A.; Resuello, R. R. G.; Lupu, F.; Barlow,
P. N.; Lambris, J. D. New analogs of the clinical complement inhibitor
compstatin with subnanomolar affinity and enhanced pharmacokinetic
properties. Immunobiology 2013, 218, 496−505.
(30) Risitano, A. M.; Ricklin, D.; Huang, Y.; Reis, E. S.; Chen, H.;
Ricci, P.; Lin, Z.; Pascariello, C.; Raia, M.; Sica, M.; del Vecchio, L.;
Pane, F.; Lupu, F.; Notaro, R.; Resuello, R. R. G.; Deangelis, R. A.;
Lambris, J. D. Peptide inhibitors of C3 activation as a novel strategy of
complement inhibition for the treatment of paroxysmal nocturnal
hemoglobinuria. Blood 2014, 123, 2094−2101.
(31) Janssen, B. J. C.; Halff, E. F.; Lambris, J. D.; Gros, P. Structure of
compstatin in complex with complement component C3c reveals a
new mechanism of complement inhibition. J. Biol. Chem. 2007, 282,
29241−29247.
(32) Klepeis, J. L.; Floudas, C. A.; Morikis, D.; Tsokos, C. G.;
Lambris, J. D. Design of peptide analogues with improved activity
using a novel de novo protein design approach. Ind. Eng. Chem. Res.
2004, 43, 3817−3826.
(33) Walensky, L. D.; Bird, G. H. Hydrocarbon-stapled peptides:
principles, practice, and progress. J. Med. Chem. 2014, 57, 6275−6288.
(34) Chi, Z.-L.; Yoshida, T.; Lambris, J. D.; Iwata, T. Suppression of
drusen formation by compstatin, a peptide inhibitor of complement
C3 activation, on cynomolgus monkey with early-onset macular
degeneration. Adv. Exp. Med. Biol. 2010, 703, 127−135.
(35) Yehoshua, Z.; Rosenfeld, P. J.; Albini, T. A. Current clinical trials
in dry AMD and the definition of appropriate clinical outcome
measures. Semin. Ophthalmol. 2011, 26, 167−180.
(36) Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters, C. L.;
Beyreuther, K. Substitutions of hydrophobic amino acids reduce the
amyloidogenicity of Alzheimer’s disease beta A4 peptides. J. Mol. Biol.
1992, 228, 460−473.
(37) Knerr, P. J.; Tzekou, A.; Ricklin, D.; Qu, H.; Chen, H.; van der
Donk, W. A.; Lambris, J. D. Synthesis and activity of thioether-
containing analogues of the complement inhibitor compstatin. ACS
Chem. Biol. 2011, 6, 753−760.
(38) Smadbeck, J.; Peterson, M. B.; Khoury, G. A.; Taylor, M. S.;
Floudas, C. A. Protein WISDOM: a workbench for in silico de novo
design of biomolecules. J. Visualized Exp. 2013, e50476−e50476.
(39) Rajgaria, R.; McAllister, S. R.; Floudas, C. A. Distance
dependent centroid to centroid force fields using high resolution
decoys. Proteins 2008, 70, 950−970.
(40) Güntert, P. Automated NMR structure calculation with
CYANA. Methods Mol. Biol. 2004, 278, 353−378.
(41) Güntert, P.; Mumenthaler, C.; Wüthrich, K. Torsion angle
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